At AVMBioMed, we believe that good information is critical to good science, whether basic or applied. We utilize a sensitive and reproducible technology to access the deepest pool of cellular information: the proteome. We then analyze, synthesize, and assemble this data to provide you with the most complete picture possible of what was occurring in your biological system. Our clients include academic investigators, government agencies, clinical research organizations, and pharmaceutical companies of all sizes. Regardless of your research interest or application, if you could benefit from a more complete and physiologic view of your project, we will work with you to acquire it.
AVMBioMed maintains state-of-the-art laboratory facilities in the center of the bio-pharmaceutical corridor in Malvern, PA, just 20 miles northwest of Philadelphia. We are fully equipped to handle our product applications in-house, and are experts in working with the immense datasets we routinely acquire. We maintain our own proprietary proteomic database that affords us an unparalleled ability to “see” and report on the complex and dynamic events going on within cells, sera, or other complex mixtures. We pride ourselves on making our clients better at what they do. Our final product is not information, but rather an informed client.
Daniel Devor, Ph.D.
Department of Cell Biology
University of Pittsburgh
Daniel Devor received his PhD in Physiology from SUNY Buffalo under the guidance of Dr. Michael Duffey, after which he did postdoctoral work with Dr. Raymond Frizzell at the University of Alabama at Birmingham. He is currently Professor of Cell Biology at the University of Pittsburgh, where he has been since 1995. Having authored roughly 50 peer-reviewed scientific publications and received over $6 million in funding from both NIH and private foundations, Dr. Devor is a worldwide expert in the regulation of channels and transporters that control membrane trafficking and organelle biogenesis. He has made seminal contributions to the understanding of both the basic science and its relevance to disease, particularly Cystic Fibrosis. Dr. Devor was an early adopter of (and strong advocate for) the Snapshot Proteomic approach.
Arthur Haas, Ph.D.
Roland Coulson Professor and Chairman
Department of Biochemistry and Molecular Biology
LSU Health Sciences Center, School of Medicine
Dr. Haas obtained his Bachelor of Science in Biochemistry from Texas Christian University in 1974. His Doctorate in Biochemistry was awarded in 1979 by Northwestern University School of Medicine in Chicago. From 1979 to 1983, Dr. Haas was on the staff of the Institute for Cancer Research of the Fox Chase Cancer Center in Philadelphia where he was a NIH postdoctoral fellow. During this time he co-discovered the role of ubiquitin in protein turnover with Irwin Rose, Avram Hershko, and Aaron Ciechanover, who shared the 2004 Nobel Prize in Chemistry for this work. Since 1983, he has been a faculty member in the Department of Biochemistry at the Medical College of Wisconsin and in 2004 joined the LSU Health Sciences Center as Roland Coulson Professor and Head of the Department of Biochemistry & Molecular Biology. Dr. Haas has authored over 120 papers, reviews, and book chapters focused on cell regulation by ubiquitin and other Class 1 ubiquitin-like proteins, particularly ISG15. He has also served on numerous editorial boards, study sections, and scientific advisory panels in addition to visiting professorships at the University of Coimbra (Portugal), and the Institute of Biological Chemistry of the University of Urbino, Italy.
Michelle Loch, M.D.
Assistant Professor of Clinical Medicine
Section of Hematology and Oncology
LSU Health Sciences Center, School of Medicine
Dr. Michelle Loch joined LSUHSC Section of Hematology and Oncology in 2012. Board Certified in Internal Medicine, Hematology and Oncology she earned her undergraduate degree from Virginia Commonwealth University and her M.D. from St. George’s University School of Medicine. She completed internal medicine internship and residency at the University of Virginia and hematology and oncology fellowship at the Boston University Medical Center. Her clinical interests include breast and gynecologic malignancies, though she sees all types of hematologic and oncologic disorders.
Her research interests included heath disparities in cancer care and minority clinical trial enrollment.
Craig Leach, Ph.D.
Scientific Leader and GSK Fellow
Craig Leach received his PhD in Microbiology from the University of Virginia in the laboratory of Dr. David Brautigan, after which he moved to Harvard University to conduct his postdoctoral research in the laboratory of Dr. Matthew Michael. It was at this time he began researching the role of ubiquitylation and SUMOylation in DNA replication and repair. Dr. Leach next worked at Progenra, Inc, eventually leading their early stage discovery programs focused on developing modulators of the ubiquitin pathway. For the past six years Dr. Leach has worked at GSK on multiple preclinical and clinical programs spanning multiple therapeutic areas.
Does joining an exciting and growing team focused on redefining the proteomics industry should like a good fit for you? We’re hiring for the following positions!
We are currently seeking a bioinformatics expert knowledgeable in R and Unix. Experience with STATA and SAS is a plus. Compensation is commensurate with education and experience. Submit a cover letter, a C.V. or resume, and contact information for at least three references to firstname.lastname@example.org with “Bioinformatics Associate” in the subject line.
We are currently seeking laboratory technicians to perform proteomic screens, in addition to a variety of other research functions. Basic laboratory proficiency and a bachelor’s degree are required. Experience with microarrays (DNA or protein) is a plus, but not required. Compensation is commensurate with education and experience. Submit a cover letter, a C.V. or resume, and contact information for at least three references to email@example.com with “Research Technician” in the subject line.